Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Janssen
Woman and Man Max 99 years
Janssen R&D Ireland
Update Il y a 4 ans
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
To demonstrate the non-inferiority of TMC435 versus TVR, both given in combination with PegIFNα-2a and RBV, by less than 12%, with respect to the proportion of subjects with SVR 12 weeks after the pla...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag B.V
Update Il y a 4 ans
Is premorbid functioning a predictor of outcome in patients with early onset psychosis treated with Risperdal Consta?
To test the hypothesis that patients with good premorbid functioning, as assessed using the Premorbid Adjustment Scale, will respond better to treatment as measured by changes from baseline on the PAN...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Janssen Cilag International
Update Il y a 4 ans
Etude DARZALEX : étude de phase 1b-2 randomisée visant à évaluer le daratumumab en association avec l’atézolizumab comparé à l’atézolizumab seul chez des patients ayant un cancer du poumon non à petites cellules avancé ou métastatique et préalablement traités. [essai clos aux inclusions]
Le cancer du poumon, 4ème cause de cancer en France, peut prendre deux formes différentes : « à petites cellules » ou « non à petites cellules », ce dernier étant la forme la plus fréquente. Il existe...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Immunothérapie - Vaccinothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures, Followed by an Open-Label Extension Study
The primary objectives of this study are to compare the efficacy, safety, and tolerability of carisbamate as adjunctive treatment of partial onset seizures, relative to placebo, as measured by the: -P...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
Janssen-Cilag CR010519 : Essai de phase 2 évaluant l’efficacité d’un traitement par bortezomib, chez des patients ayant un myélome multiple ayant répondu à un précédant traitement à base de bortezomib. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité et la tolérance d’un traitement par bortezomib, chez des patients ayant un myélome multiple ayant répondu à un précédant traitement à base de bortezo...
Country
France
organs
Myélomes
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Janssen Pharmaceuticals
Update Il y a 4 ans
The ‘Can Do Ramadan’ Study
Background and study aims There are over one billion Muslims in the world with the majority participating in Ramadan which is an integral part of Islamic identity. Muslims observing Ramadan are requi...
Country
None
organs
None
Specialty
None
Opened trial
More information
Man Max 99 years
Janssen Oncology, Inc
Update Il y a 4 ans
An Expanded Access Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Completed CB7630 Clinical Study COU-AA-001
To provide access to CB7630 for patients who have completed 12 cycles of abiraterone acetate treatment and continue to receive clinical benefit from such a treatment.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants greater than 6 to less than 12 Years of Age
To evaluate the efficacy and safety of ustekinumab in pediatric subjects aged ≥6 through <12 years with moderate to severe chronic plaque psoriasis.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen Sciences Ireland UC
Update Il y a 4 ans
Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection
To evaluate the antiviral effect of repeated oral dosing of JNJ-53718678 compared to placebo in healthy adult subjects infected through inoculation with RSV-A Memphis 37b virus.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wim Janssens, MD PhD
Update Il y a 4 ans
BACE Trial Substudy 2 - FarmEc Substudy
A second sub-analysis of the BACE trial will include a detailed cost-effectiveness study.
Country
None
organs
None
Specialty
None
Opened trial
More information
Previous
11
12
13
14
15
16
17
18
19
20
Next